These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11873630)

  • 41. Immunotolerant functions of HLA-G.
    Carosella ED; Dausset J; Rouas-Freiss N
    Cell Mol Life Sci; 1999 Mar; 55(3):327-33. PubMed ID: 10228553
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HLA-G inhibits rolling adhesion of activated human NK cells on porcine endothelial cells.
    Forte P; Pazmany L; Matter-Reissmann UB; Stussi G; Schneider MK; Seebach JD
    J Immunol; 2001 Nov; 167(10):6002-8. PubMed ID: 11698480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HLA-G inhibits the allogeneic proliferative response.
    Riteau B; Menier C; Khalil-Daher I; Sedlik C; Dausset J; Rouas-Freiss N; Carosella ED
    J Reprod Immunol; 1999 Jul; 43(2):203-11. PubMed ID: 10479056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer.
    Lefebvre S; Antoine M; Uzan S; McMaster M; Dausset J; Carosella ED; Paul P
    J Pathol; 2002 Mar; 196(3):266-74. PubMed ID: 11857488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HLA Class I protein expression in the human placenta.
    Blaschitz A; Hutter H; Dohr G
    Early Pregnancy (Cherry Hill); 2001 Jan; 5(1):67-9. PubMed ID: 11753519
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition.
    Riteau B; Menier C; Khalil-Daher I; Martinozzi S; Pla M; Dausset J; Carosella ED; Rouas-Freiss N
    Int Immunol; 2001 Feb; 13(2):193-201. PubMed ID: 11157852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune modulation of HLA-G dimer in maternal-fetal interface.
    Kuroki K; Maenaka K
    Eur J Immunol; 2007 Jul; 37(7):1727-9. PubMed ID: 17587197
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways.
    Le Rond S; Gonzalez A; Gonzalez AS; Carosella ED; Rouas-Freiss N
    Immunology; 2005 Nov; 116(3):297-307. PubMed ID: 16236119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells.
    Rajagopalan S; Long EO
    J Exp Med; 1999 Apr; 189(7):1093-100. PubMed ID: 10190900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure, expression and function of HLA-G in renal cell carcinoma.
    Seliger B; Schlaf G
    Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells.
    Münz C; Holmes N; King A; Loke YW; Colonna M; Schild H; Rammensee HG
    J Exp Med; 1997 Feb; 185(3):385-91. PubMed ID: 9053439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes.
    Romagnani C; Pietra G; Falco M; Mazzarino P; Moretta L; Mingari MC
    Hum Immunol; 2004 May; 65(5):437-45. PubMed ID: 15172443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells?
    Aractingi S; Briand N; Le Danff C; Viguier M; Bachelez H; Michel L; Dubertret L; Carosella ED
    Am J Pathol; 2001 Jul; 159(1):71-7. PubMed ID: 11438456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?
    Rouas-Freiss N; Marchal RE; Kirszenbaum M; Dausset J; Carosella ED
    Proc Natl Acad Sci U S A; 1997 May; 94(10):5249-54. PubMed ID: 9144223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HLA-G and lymphoproliferative disorders.
    Amiot L; Le Friec G; Sebti Y; Drénou B; Pangault C; Guilloux V; Leleu X; Bernard M; Facon T; Fauchet R
    Semin Cancer Biol; 2003 Oct; 13(5):379-85. PubMed ID: 14708718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?
    Amiot L; Ferrone S; Grosse-Wilde H; Seliger B
    Cell Mol Life Sci; 2011 Feb; 68(3):417-31. PubMed ID: 21063893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Non-classical human leukocyte antigen (HLA) tissue types--from implantation to transplantation].
    Hviid TV
    Ugeskr Laeger; 2006 Jan; 168(5):461-6. PubMed ID: 16472433
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [HLA-G: an immunoregulatory non classical class I HLA molecule].
    Ksouri H; Bardi R; Mellouli F; Bejaoui M
    Arch Inst Pasteur Tunis; 2009; 86(1-4):27-38. PubMed ID: 20707218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Could the functional expression of HLA-G be exploited for successful stem cell transplantation and engraftment?
    Williams MA
    J Hematother Stem Cell Res; 2003 Dec; 12(6):757-8. PubMed ID: 14977484
    [No Abstract]   [Full Text] [Related]  

  • 60. HLA-G polymorphisms: ethnic differences and implications for potential molecule function.
    van der Ven K; Skrablin S; Ober C; Krebs D
    Am J Reprod Immunol; 1998 Sep; 40(3):145-57. PubMed ID: 9764358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.